Sign in
Active, not recruitingPhase 2/3

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Key facts

Who runs it
AO GENERIUM
Where
Russia5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
32 people, planned
Started
30 Nov 2021
Expected to end
Mar 2028
Type of study
Interventional, 3 groups
Treatments tested
  • GNR-055 1.0-2.0-3.0 mg/kg
  • GNR-055 2.0 mg/kg
  • GNR-055 3.0 mg/kg
Record updated
21 September 2026

Who can take part

Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Signed inform consent
  • Verified diagnosis of MPS II (Hunter syndrome)
  • Naïve patients or patients who have received standard ERT whit idursulfase products
  • No contraindications for lumbar puncture as judged by the Investigator
  • Willingness and ability to follow study procedures

Who cannot take part

  • Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study
  • Clinically pronounced hypersensitivity to ID2S or any other component of the drug product
  • History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation
  • Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.

The 3 groups in the trial

  • Adult: GNR-055Treatment being tested

    GNR-055: 1.0-2.0-3.0 mg/kg

    Treatment: GNR-055 1.0-2.0-3.0 mg/kg

  • Paediatric: GNR-055 2.0 mg/kgTreatment being tested

    GNR-055 2.0 mg/kg

    Treatment: GNR-055 2.0 mg/kg

  • Paediatric: GNR-055 3.0 mg/kgTreatment being tested

    GNR-055 3.0 mg/kg

    Treatment: GNR-055 3.0 mg/kg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicenter, Open-Label, Multi-cohort Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Drug Product GNR 055 (JSC "GENERIUM", Russia) in Patients With Mucopolysaccharidosis Type II
Record updated
21 September 2026